Alexander Kamb
Investor Relations Contact bei ZEHNDER GROUP AG
Profil
Alexander Kamb is the founder of A2 Biotherapeutics, Inc. (founded in 2018) and currently holds the position of Director & Chief Scientific Officer.
He is also currently working as a Senior Manager-Investor Relations & Communications at Zehnder Group AG.
In the past, Dr. Kamb worked as a Director at Surrozen Operating, Inc.
Aktive Positionen von Alexander Kamb
| Unternehmen | Position | Beginn |
|---|---|---|
| ZEHNDER GROUP AG | Investor Relations Contact | - |
A2 Biotherapeutics, Inc.
 A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | Founder | 01.01.2018 |
Ehemalige bekannte Positionen von Alexander Kamb
| Unternehmen | Position | Ende |
|---|---|---|
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZEHNDER GROUP AG | Producer Manufacturing |
| Private Unternehmen | 2 |
|---|---|
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | Commercial Services |
